FREMONT, Calif., Jan. 2 /PRNewswire/ -- Abgenix, Inc. (Nasdaq: ABGX) today
announced that the U.S. Patent and Trademark Office has issued another patent
to Abgenix relating to the company's XenoMouse(TM) technology, its core
technology for generating fully human monoclonal antibodies.
The newest patent, entitled "Human Antibodies From Immunized XenoMice,"
U.S. Patent Number 6,150,584, covers transgenic mice with certain specified
genetic modifications allowing them to produce fully human antibodies.
Abgenix's XenoMouse transgenic mouse strains possess an immune system in which
the mouse antibody-producing genes have been inactivated and functionally
replaced by human antibody-producing genes. The resulting immune response
from the repeated administration of a target antigen into a XenoMouse is the
production of antibodies that are fully human and specific to the antigen.
This patent marks the fourth U.S. patent that Abgenix has received
claiming its XenoMouse technology and builds on the company's proprietary
position in the field of human monoclonal antibodies. Abgenix also has
granted patents in Europe and Japan.
Abgenix is a biopharmaceutical company focused on the development and
commercialization of antibody therapies for a variety of diseases. The
company developed XenoMouse(TM) technology to enable the rapid generation of
high affinity, fully human antibody product candidates to essentially any
disease target appropriate for antibody therapy. Abgenix uses its XenoMouse
technology to build a large and diversified product portfolio through the
establishment of licensing arrangements with multiple pharmaceutical,
biotechnology and genomics companies and through the development of its own
internal proprietary products. For more information on Abgenix, visits the
company's website at http://www.abgenix.com.
Statements made in this press release about Abgenix's XenoMouse
technology, product development activities and collaborative arrangements
other than statements of historical fact, are forward looking statements and
are subject to a number of uncertainties that could cause actual results to
differ materially from the statements made, including risks associated with
the success of clinical trials, the progress of research and product
development programs, the regulatory approval process, competitive products,
future capital requirements and the extent and breadth of Abgenix's patent
portfolio. Please see Abgenix's public filings with the Securities and
Exchange Commission for information about risks that may affect Abgenix.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
Company News On-Call:
http://www.prnewswire.com/comp/126548.html or fax,
800-758-5804, ext. 126548
CONTACT:
Ina Cu-Unjieng, manager, Investor/Public
Relations of Abgenix, Inc., 510-608-4662
|
